Alexion, AstraZeneca's rare disease division, has agreed to buy a portfolio of preclinical gene therapy programs and enabling technologies from competitor Pfizer for up to $1 billion, plus tiered royalties on sales.
French plant ingredients supplier Roquette, which is also is a leading player in naturally-derived pharmaceutical excipients, has agreed to acquire Qualicaps, a producer of hard capsules and pharmaceutical processing equipment for oral dosage.
Braskem has completed the expansion of production capacity for its biobased ethylene plant in the petrochemical complex of Triunfo, Rio Grande do Sul, Brazil.
Compared with Q2 last year AkzoNobel, a coatings and sustainable paints company, saw revenue 4% down on unfavorable exchange rates, 3% up in constant currencies, and considerable increases in both its operating income and net cash from operating activities.
Swiss pharmaceutical company Roche will collaborate with Cambridge, Massachusetts-based US biotech Alnylam Pharmaceuticals to further develop its drug zilebesiran for the treatment of hypertension. The therapeutic, which is in Phase 2 clinical trials, uses the cellular mechanism RNA interference (RNAi) for targeted gene silencing.
Over 30 drugs, including painkiller fentanyl and anesthetic lidocaine, may see disruptions in supply after a tornado destroyed a warehouse at Pfizer's Rocky Mount facility in North Carolina, US, last week.
Bayer adjusted its full-year outlook for 2023 downward, mainly due to a significant further decline in sales of glyphosate-based products. The group has thus joined the ranks of chemical companies that have cut their annual targets in recent days and weeks.
SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”
Zeta, an Austrian engineering specialist for biopharmaceutical process plants, acquired a 20% share in Swiss company CB Consultancy. The transaction was completed by Jul. 14, 2023.
Gelest, a Mitsubishi Chemical Group company, recently broke ground on its latest production facility. The new facility is 4,600 square meters and is located at Galest’s global headquarters in Morrisville, PA. Completion of the facility is expected by Sept. 2024. The new facility enhances Gelest’s production capabilities in various customer applications such as microelectronics, medical devices, and advanced thermal coatings.
Block Solutions is a Tampere, Finland-based company that has developed environmentally friendly block-modules made of recycled plastics or in combination with local excess raw materials.
CEFIC, the European Chemical Industry Council, expects the EU27 chemical production to decline by about 8% in 2023 compared to the previous year, with no imminent recovery of chemical demand in Europe.
Upperton Pharma Solutions, a UK contract development and manufacturing organization (CDMO), has completed construction of its new development and GMP manufacturing headquarters in Nottingham, UK. The company said it has invested £15 million in the new 50,000-square-foot facility.
Major drugmaker Eli Lilly has agreed to acquire Versanis Bio, a privately held obesity drug maker, for up to $1.925 billion. The transaction is subject to customary closing conditions.
Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi XDC on the Hong Kong Stock Exchange. Upon completion of the proposed listing, Wuxi XDC will remain a consolidated subsidiary.
ExxonMobil has acquired Denbury, a carbon capture, utilization, and storage (CCUS) and enhanced oil recovery company. The all-stock transaction is valued at €4.5 billion.
BP will develop two offshore wind projects as its entry into Europe's offshore wind market. The North Sea sites, with a 4GW total potential generating capacity, will be located 130 and 150 km offshore at 40 m depths.
KHUA plans to build a production plant for high-quality powder coatings in Zhanjiang and concludes a supply agreement for the precursor neopentyl glycol with BASF.
Maurizio Sartorato has joined international API supplier Olon as Vice President of the group's Biotech division. In his new role, he will be a member of Olon’s leadership team.
Germany-headquartered healthcare company Fresenius Medical Care has appointed Martin Fischer as its new chief financial officer, effective Oct. 1, 2023.
US scientific services supplier Thermo Fisher Scientific has agreed to acquire CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash. The transaction, which is expected to be completed by the end of 2023, is subject to customary closing conditions, including regulatory approvals.
Teva Pharmaceuticals considers selling its $2 billion active pharmaceutical ingredients (API) unit as part of its "Pivot to Growth" strategy.
Shell CEO, Wael Sawan, contemplates another headquarters move amidst the introduction of windfall taxes in the UK. Questions about the state of production and energy costs are also of concern.
The Thailand branch of German engineering contractor Thyssenkrupp Uhde has won a contract by BASF to provide engineering services and proprietary equipment supply for its new non-ionic surfactant (NIS) plant at its Zhanjiang Verbund Site Project in Guangdong Province, China.
Solenis, a specialty chemicals manufacturer for water-intensive industries, has completed its acquisition of Diversey, a hygiene and cleaning products provider, in an all-cash transaction valued at ~ $4.6 billion.
A survey published by the Ifo economic institute indicates that the German chemical industry fell significantly in June.
LyondellBasell, a global leader in polymer and polyolefin technologies, has successfully acquired Mepol Group, a manufacturer of high-performing recycled compounds based in Italy and Poland.
Avantium, a technology provider in renewable chemistry, has agreed to partner with SCG Chemicals (SCGC), an integrated chemical player and innovator in Asia, to further develop CO2-based polymers and to scale-up to a pilot plant with an indicative annual capacity of 10 t.
BASF and Yara Clean Ammonia (YCA), a unit of Norwegian fertilizer producer Yara, have teamed up on a joint study to develop and build a world-scale low-carbon blue ammonia production facility with carbon capture in the US Gulf Coast region.
Results from AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan clinical trials were released this week. The antibody drug, also known as Dato-DXd, was developed in partnership between the two companies and aims to help patients with the most common lung cancer live longer without worsening their condition when compared to standard treatments. However, the announcement fell short of expectations, leading to a decline in AstraZeneca's shares.
Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.
Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5 billion, which marks a strategic move to focus on innovative medicines and growth opportunities.
Chinese drugmaker CSPC Pharmaceutical announced on Jun. 28, 2023, that it has signed a strategic partnership agreement with Pfizer to launch a local brand of the Covid-19 oral therapeutic treatment Paxlovid in China. The goal is to improve access to this treatment in China.
Belgian chemical major Solvay has reached a $393 million deal with the US state of New Jersey to remedy contamination from poly- and per-fluorinated alkyl substances (PFAS) – also known as “forever chemicals – caused by its subsidiary Solvay Specialty Polymers.
French specialty chemicals company Arkema plans to acquire the 54% majority stake held by Glenwood Private Equity in South Korea-listed PI Advanced Materials (PIAM) for €728 million and fully consolidate the holding. The remaining 46% of equity will continue to be listed in South Korea.
